drugset / Trial / NCT04887025
Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma
Phase 1
Unknown
25 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou Rongu Biotechnology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a dose-escalation, single-arm, single-center open study which aims to evaluate the maximum tolerated dose (MTD) and dose-dependent toxicity (DLT) of a novel oncolytic vaccinia virus expressing bispecific antibody RGV004 in patients with relapsed/refractory B-cell lymphoma,
Timeline
- Start
- 2022-02-08
- Primary completion
- 2023-03-15
- Completion
- 2025-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RGV004 | Unknown | — | — |